Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Hans-Peter Kapprell"'
Publikováno v:
BIO. 2:27-36
Autor:
Carsten Buenning, Boris Heinrich, Andreas Maurer, Florian Kramer, Hubert Kalbacher, Hans-Peter Kapprell, Alfredo Narvaez, Thomas Flad
Publikováno v:
ASSAY and Drug Development Technologies. 9:549-553
Protease impurities in raw materials used in enzyme immunoassays can impair assay performance. This risk may be greatly decreased if incoming protein-based raw materials are controlled for protease impurities or if protease inhibitors are used in the
Autor:
Michael Oer, Sushil G. Devare, Gerald Schochetman, Michael Hausmann, Andreas Goller, Myriam Stieler, Xiaoxing Qiu, Hans-Peter Kapprell
Publikováno v:
Diagnostic Microbiology and Infectious Disease. 67:61-69
In comparison to current on-market assays, the ARCHITECT rHTLV-I/II assay is the first fully automated assay that simultaneously detects human T-cell lymphotropic virus type I (HTLV-I) and type II (HTLV-II) in human serum and plasma. Specificity was
Autor:
Hans-Peter Kapprell, Ferruccio Bonino, Stephanos J. Hadziyannis, Patrick Marcellin, Rami Moucari, M. Popescu, Vivien Rothe, Cihan Yurdaydin, Maurizia Rossana Brunetto
Publikováno v:
Hepatology International
Purpose To investigate the durability of response to peginterferon alfa-2a up to 5 years post-treatment and factors associated with response in hepatitis B e-antigen (HBeAg)-negative patients. Methods HBeAg-negative patients received peginterferon al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d39088b77fa5204e7f067ff213978734
http://hdl.handle.net/11568/208489
http://hdl.handle.net/11568/208489
Publikováno v:
Retrovirology, Vol 8, Iss Suppl 1, p A254 (2011)
Retrovirology
Retrovirology
Background Detection of HTLV infection continues to be important to control spread of human retroviruses and to protect safety of blood supply. The ARCHITECT rHTLV-I/II assay is a chemiluminescence-based immunoassay, which utilizes HTLV-I, and HTLV-I
Autor:
Christian Beckert, Markus Roebbecke, Doris Krams, Loredana Piro, Christian Popp, Marina Luciani, Hans-Peter Kapprell, Carsten Buenning, Lucinda Queirós
Publikováno v:
Diagnostic microbiology and infectious disease. 70(4)
A low initial reactive rate for screening assays is important for time- and cost-effective infectious disease testing. Therefore, the new ARCHITECT HBsAg Qualitative screening assay, in conjunction with the new ARCHITECT HBsAg Qualitative Confirmator
Autor:
Gesa Jonas, Gerald Schochetman, Jane D. Bryant, Jeffery C. Hunt, Catherine A. Brennan, Sushil G. Devare, Eva Sickinger, Alex W. Yem, Hans-Peter Kapprell, Michael Hausmann, Andreas Goller, Myriam Stieler
Publikováno v:
Transfusion. 48(4)
BACKGROUND: Before the introduction of human immunodeficiency virus (HIV) combination assays, serologic diagnosis of HIV infection was performed with assays that detected either antibodies or p24 antigen. Owing to the capability to detect the early a
Autor:
Michael Hausmann, José M. Echevarría, Hans-Peter Kapprell, Ana Avellón, Angela Vockel, Gesa Jonas
Publikováno v:
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 35(4)
Background and objectives Compliance with current regulations regarding the prevention of hepatitis C virus (HCV) transmission in the blood transfusion setting requires the use of sensitive assays for HCV antibody (anti-HCV) detection, which should,
Publikováno v:
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 34(2)
Introduction: The ARCHITECT Anti-HCV assay is a fully automated high throughput chemiluminescent microparticle immunoassay (CMIA) for the detection of antibodies to structural and nonstructural proteins of the hepatitis C virus (HCV). To further enha
Autor:
Gerald Schochetman, Hans-Peter Kapprell, Eva Sickinger, Jeffrey C Hunt, Sushil G. Devare, Arnold Sandridge, David Daghfal, Daniel West, Boris Kaufman, Myriam Stieler
A collaborative multicenter study was conducted to evaluate the sensitivity, specificity, and precision of a three-step, fully automated, qualitative microparticle-based enzyme-linked immunoassay (AxSYM HIV Ag/Ab Combo; Abbott Laboratories), designed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a39181bbfa59fa3856998241d0e888c8
https://europepmc.org/articles/PMC321662/
https://europepmc.org/articles/PMC321662/